Fig. 8

MiR-340-5p suppressed tumor growth by enhancing CD8⁺ T-TILs in vivo. a KMT5A significantly abrogated the lower tumor growth rate caused by miR-340-5p. Statistical tests were performed using tumor volume data on Day 24. b-d IHC analysis of Ki-67 (b), COP1 (c) and CD8 (d) expression in tumors, as indicated. The CD8⁺ T-TIL percentage was increased under miR-340-5p treatment and significantly reversed by overexpressing KMT5A, as shown by IHC analysis. e Representative flow cytometry data and cumulative data for CD8⁺ T-TILs isolated from murine model tumors. In all experiments, cells were first gated on the CD3⁺ population and then on the CD8⁺ population. f Representative flow cytometry data and cumulative data for CD69-positive CD8⁺ T-TILs. g IHC analysis of granzyme B and perforin. Asterisk (*) indicates a significant difference. *, P < 0.05